Momenta Pharmaceuticals Falls 17% on Patent Infringement Ruling

Loading...
Loading...
Momenta Pharmaceuticals
MNTA
is trading lower on the session after announcing that Teva Pharmaceutical
TEVA
received a favorable ruling in COPAXONE patent infringement case. The decision is subject to appeal. Craig Wheeler, President and Chief Executive Officer of Momenta. "We are disappointed that the court determined that Teva's patents were valid and infringed, and we look forward to reading the full opinion to understand its reasoning. We remain confident in our legal position and we intend to appeal." Momenta Pharmaceuticals is currently trading at $14.02, a loss of $2.99 or 17.61%.
Posted In: Intraday UpdateMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...